Home » Topics » Dermatologic, BioWorld Science

Dermatologic, BioWorld Science
RSS

Hoth Therapeutics initiates confirmatory study of the AEA-loaded-Z pods in models of lupus

Nov. 7, 2019

Further interim data presented from phase Ib study of EDP-1815 in patients with psoriasis

Nov. 6, 2019

Clinical development of MOR-106 for atopic dermatitis ended for futility

Oct. 29, 2019

BioCryst Pharmaceuticals discloses complement factor D inhibitors

Oct. 29, 2019

Microbion announces phase Ib data for pravibismane in infected diabetic foot ulcers

Oct. 29, 2019

First subject dosed in phase II ADVISE study of etrasimod in atopic dermatitis

Oct. 29, 2019

Arcutis plans phase III program with ARQ-151 for plaque psoriasis

Oct. 28, 2019

Rapt Therapeutics studies oral CCR4 antagonist RPT-193 in first-in-human trial

Oct. 24, 2019

Ex vivo gene-corrected autologous cell therapy for chronic RDEB wounds: results of phase I/IIa trial

Oct. 24, 2019

FDA grants approval to Amzeeq topical foam for acne

Oct. 21, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 16, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
In the clinic for June 12, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Anixa, Beone, Bioinvent, Blossomhill, C4, Cellectis, Climb, Elixiron,...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...